Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-iii symbols : Bmy save search
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
first disease active update trial
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
TSVT | $4.52 -2.59% -2.65% 610K
|
|
| O: -4.02%
H: 9.35%
C: 4.84%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
therapy
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.84%
H: 1.39%
C: -0.28%
opdivo trial plus
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.03%
H: 0.87%
C: 0.38%
lung opdivo cancer cell trial benefits
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.03%
H: 0.87%
C: 0.38%
lung opdivo cancer cell trial
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
Published: 2023-08-28 (Crawled : 19:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.03%
H: 0.56%
C: -0.68%
camzyos response
AVEO Oncology Announces Completion of Enrollment in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Advanced Renal Cell Carcinoma
Published: 2023-06-27 (Crawled : 22:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.0%
fotivda renal cell study
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
Published: 2023-06-16 (Crawled : 10:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.32%
H: 2.1%
C: 1.97%
camzyos drug label food positive study
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
Published: 2023-03-30 (Crawled : 15:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.29%
H: 0.22%
C: -0.26%
lung opdivo cancer cell trial benefits
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2023-02-13 (Crawled : 00:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -1.37%
H: 0.69%
C: 0.51%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.03%
H: 1.69%
C: 1.32%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.68%
H: 1.66%
C: 1.49%
opdivo renal trial cell carcinoma nivolumab
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.62%
H: 1.24%
C: 0.45%
treatment disease meeting year one
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS)
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.24%
H: 2.12%
C: 1.61%
treatment opdivo nivolumab
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
Published: 2022-06-24 (Crawled : 20:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.2%
H: 0.48%
C: 0.43%
treatment sclerosis
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
Published: 2022-06-24 (Crawled : 20:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.2%
H: 0.48%
C: 0.43%
covid-19 response sclerosis
Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia (abatacept) Improved Survival in People Hospitalized with COVID-19
Published: 2022-06-02 (Crawled : 16:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
covid-19 treatment topline results
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Published: 2022-04-11 (Crawled : 15:20) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.09%
H: 0.55%
C: -1.54%
opdivo trial cancer phase 3 nivolumab
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab)
Published: 2022-02-25 (Crawled : 13:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
opdivo positive chmp nivolumab
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Published: 2022-02-14 (Crawled : 23:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.27%
H: 0.2%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.01%
H: 0.22%
C: -0.09%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.27%
H: 1.12%
C: -0.59%
opdivo renal trial cel cell carcinoma nivolumab
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.03%
H: 1.24%
C: 0.8%
positive phase 3 psoriasis
Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme
Published: 2020-12-23 (Crawled : 18:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.1%
H: 0.42%
C: -0.6%
phase 3 trial glioblastoma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.